Single Use Bioreactors Market | Contrive Datum Insights

The Global single-use bioreactor market was valued at US$ 3.30 Billion in 2022, and is projected to reach US$ 12.06 Billion by 2030, growing at a CAGR of 17.19% from 2023 to 2030.
{{info}}

The global single-use bioreactor market refers to the market for bioreactors that are designed for single use in the biopharmaceutical and biotechnology industries. Single-use bioreactors are typically made of plastic and are used for the production of biologics, including vaccines, monoclonal antibodies, and cell and gene therapies.

The global single-use bioreactor market has been growing rapidly in recent years, driven by a number of factors. These include the increasing demand for biologics, the shift towards more flexible and cost-effective manufacturing processes, and the development of new and innovative technologies.

Market Dynamics

Driving Factors

The global single-use bioreactors market is driven by various factors, including increasing demand for biologics, cost savings and operational flexibility, increasing technological advancements, regulatory support, and sustainability.

Increasing demand for biologics: Biologics are complex molecules that are used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Biologics require large-scale production and bioreactors are an essential tool for manufacturing them. As the demand for biologics continues to grow, so too does the demand for single-use bioreactors.

Cost savings and operational flexibility: Single-use bioreactors offer significant cost savings compared to traditional stainless steel bioreactors. They eliminate the need for cleaning and validation between batches, which reduces downtime and enables faster turnaround times. They also require less space and can be easily integrated into existing facilities, providing greater operational flexibility.

Restraining Factors

While there are several driving factors behind the growth of the global single-use bioreactor market, there are also some restraining factors that are worth noting. These include:

Limited scalability: Single-use bioreactors are typically smaller than traditional stainless steel bioreactors, which limits their scalability. While multiple single-use bioreactors can be used in parallel to increase production capacity, this can lead to higher costs and increased complexity.

Cost of consumables: While single-use bioreactors offer cost savings in terms of cleaning and validation, they do require the use of disposable plastic bags, filters, and other consumables. The cost of these consumables can be high, particularly for large-scale production runs.

Opportunity Factors

The global single-use bioreactor market presents a significant opportunity for growth in the coming years, driven by several factors such as increased demand for biopharmaceuticals, rising adoption of single-use technologies, and increasing focus on reducing manufacturing costs and improving efficiency.

One of the key drivers of the market is the increasing demand for biopharmaceuticals, which are used in the treatment of a wide range of diseases. As biopharmaceuticals are typically more complex and difficult to produce than traditional pharmaceuticals, the use of single-use bioreactors can help to streamline the manufacturing process and reduce costs. Additionally, the growing prevalence of chronic diseases and the aging population is expected to drive demand for biopharmaceuticals, further fueling the growth of the single-use bioreactor market.

Another important factor contributing to the growth of the market is the increasing adoption of single-use technologies by biopharmaceutical manufacturers. Single-use bioreactors offer several advantages over traditional stainless-steel bioreactors, including lower costs, reduced risk of contamination, and greater flexibility in terms of scaling up or down production. These benefits are leading many biopharmaceutical manufacturers to shift towards single-use technologies, further driving the growth of the market.

In addition, the market is also being driven by increasing focus on reducing manufacturing costs and improving efficiency. Single-use bioreactors offer a number of cost advantages over traditional stainless-steel bioreactors, including reduced capital expenditure, lower operating costs, and less downtime for cleaning and maintenance. As a result, many biopharmaceutical manufacturers are turning to single-use bioreactors as a way to reduce costs and improve efficiency in their manufacturing processes.

Overall, the global single-use bioreactor market presents a significant opportunity for growth in the coming years, driven by increasing demand for biopharmaceuticals, rising adoption of single-use technologies, and growing focus on reducing manufacturing costs and improving efficiency.

Challenge Factors

While the global single-use bioreactor market presents significant growth opportunities, there are also several challenges that may impact its growth trajectory. Some of the key challenges include:

Limited scalability: Single-use bioreactors have limitations in terms of scalability when compared to traditional stainless-steel bioreactors. This can be a challenge for biopharmaceutical manufacturers that need to produce large quantities of biologics.

Supply chain disruptions: The single-use bioreactor market is highly reliant on raw materials and components from a few key suppliers. Any disruption in the supply chain can have a significant impact on the market.

Regulatory challenges: Single-use bioreactors are relatively new technology, and regulatory agencies are still developing standards and guidelines for their use. This can create uncertainty for biopharmaceutical manufacturers, which may delay the adoption of single-use bioreactors.

Environmental concerns: The disposal of single-use bioreactors can have negative environmental impacts. The use of single-use plastics can contribute to plastic waste and pollution.

Cost concerns: While single-use bioreactors offer several cost advantages, they can be more expensive on a per-batch basis than traditional stainless-steel bioreactors. This can be a challenge for smaller biopharmaceutical manufacturers with limited budgets.

Segmentation Analysis

Product Scope Outlook

Among these product types, the stirred-tank bioreactors segment is expected to hold the largest market share in the global single-use bioreactor market. This is due to their versatility and widespread use in biopharmaceutical manufacturing, as well as the availability of a wide range of options and sizes from different vendors.

The wave-induced bioreactors segment is also expected to see significant growth, driven by their ability to provide gentle agitation and aeration to the cell culture, which can be important for the production of certain biologics.

Overall, the global single-use bioreactor market is expected to continue growing due to the increasing demand for biologics, the cost savings and operational flexibility offered by single-use bioreactors, and the development of new and innovative technologies.

Type Scope Outlook

The single-use bioreactor market can be segmented into two main types based on the mode of operation: Stirred-Tank Bioreactors (STR) and Wave-Induced Bioreactors (WIB). Stirred-Tank Bioreactors (STR) are traditional bioreactors that use mechanical agitation to mix the cell culture. Wave-Induced Bioreactors (WIB) are a newer technology that uses a wave-like motion to agitate the cell culture.

The single-use bioreactor market can be segmented into various applications, including Biopharmaceuticals, Academic & Research Institutes, Contract Research Organizations (CROs), and Contract Manufacturing Organizations (CMOs).

The single-use bioreactor market can be segmented based on the type of cells used in the bioreactor, such as Mammalian Cells, Bacterial Cells, Yeast Cells, and Other Cells.

The single-use bioreactor market can be segmented based on the end-users of the technology, such as Biopharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs).

Each of these segments presents its unique opportunities and challenges. For example, the biopharmaceutical segment is expected to grow rapidly due to the increasing demand for biologics, while the academic and research institutes segment is expected to be driven by the need for basic research and development of new therapies. Similarly, the adoption of single-use bioreactors in CMOs is expected to drive the growth of the market, as CMOs are increasingly adopting these technologies to improve manufacturing efficiency and reduce costs.

Overall, the single-use bioreactor market is a highly dynamic and evolving market, with new applications and cell types being developed regularly. As a result, the market is expected to continue to grow and evolve in the coming years, presenting significant opportunities for manufacturers and investors alike.

Regional Analysis

North America and Europe are currently the largest markets for single-use bioreactors, driven by the presence of a well-established biopharmaceutical industry and a strong regulatory environment. The United States, in particular, is a major market for single-use bioreactors, with many of the leading biopharmaceutical manufacturers based there.
{{info2}}

The Asia Pacific region is expected to see the fastest growth in the single-use bioreactor market, driven by the increasing demand for biologics and the growing biopharmaceutical industry in countries such as China, India, and South Korea. These countries are investing heavily in biopharmaceutical manufacturing infrastructure and are expected to become major players in the global biopharmaceutical industry in the coming years.

Scope Of Report:

The Global Single-use Bioreactors Market has been segmented into:

By Product Scope

Single-use bioreactor systems

• Up to 10L
• 11-100L
• 101-500L
• 501-1500L
• Above 1500L

Single-use media bags

• 2D Bags
• 3D Bags
• Others

Single-use Filtration Assemblies

• Other Products

By Type

• Stirred-tank SUBs
• Wave-induced SUBs
• Bubble-column SUBs
• Other SUBs

By Type of Cell

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cells

By Molecule Type

• Monoclonal Antibodies
• Vaccines
• Gene Modified Cells
• Stem Cells
• Other Molecules

By Application

• Research and Development (R&D) or Process Development
• Bioproduction

By End-use

• Pharmaceutical & Biopharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

By Usage Type

• Lab-scale Production
• Pilot-scale Production
• Large-scale Production

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global single-use bioreactors market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• Sartorius Stedim Biotech
• Thermo Fisher Scientific
• Danaher
• Merck KgaA
• Celltainer Biotech BV
• Getinge AB
• Eppendorf AG
• Cellexus
• PBS Biotech Inc.
• Distek Inc.
• ABEC
• Able Corporation & Biott Corporation
• G&G Technologies Inc.
• Solida Biotech GmbH
• Satake Chemical Equipment Mfg., Ltd.
• Stobbe Pharma GmbH
• bbi-biotech GmbH 

Thermo Fisher Scientific Inc. and Sartorius AG are currently the leading players in the global single-use bioreactor market, with a strong presence in North America and Europe. They offer a wide range of products and solutions for biopharmaceutical manufacturing, including single-use bioreactors and associated consumables.

Merck KGaA and Danaher Corporation (Pall Corporation) are also major players in the single-use bioreactor market, with a strong focus on innovation and the development of new technologies.

Strategic Developments

The single-use bioreactor market has seen several strategic developments in recent years, including acquisitions, mergers, and partnerships. Some of the notable ones are:

In 2021, Danaher Corporation announced the acquisition of Aldevron, a leading provider of plasmid DNA, mRNA, and protein production services. The acquisition is expected to strengthen Danaher's position in the biopharmaceutical market and enhance its ability to offer integrated solutions for gene and cell therapy manufacturing.

In 2020, Sartorius AG acquired Biological Industries, a leading provider of cell culture media and sera for the biopharmaceutical industry. The acquisition is expected to enhance Sartorius' product portfolio and expand its presence in the cell culture market.

In 2019, Thermo Fisher Scientific Inc. announced the acquisition of Brammer Bio, a leading provider of viral vector manufacturing services for gene and cell therapy applications. The acquisition is expected to enhance Thermo Fisher's position in the growing gene therapy market.